What is the difference between Retatrutide (GLP-3) and Tirzepatide?

The main difference is mechanism and research stage. Retatrutide (GLP-3) targets GLP-1 + GIP + glucagon (triple agonist) (phase 3 (investigational)) and is studied for metabolic & body-weight research; Tirzepatide targets GLP-1 + GIP (dual agonist) (approved formulations exist) and is studied for metabolic & body-weight research. Both are research-use-only compounds, not for human or animal use.

Are Retatrutide (GLP-3) and Tirzepatide approved for human use?

No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — Retatrutide (GLP-3): phase 3 (investigational); Tirzepatide: approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.

How is purity verified for Retatrutide (GLP-3) and Tirzepatide?

Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.

Research Comparison

Retatrutide (GLP-3) vs Tirzepatide

Retatrutide (GLP-3) and Tirzepatide are often compared because both sit in metabolic research. Retatrutide (GLP-3) acts on GLP-1 + GIP + glucagon (triple agonist) and is studied for metabolic & body-weight research, while Tirzepatide acts on GLP-1 + GIP (dual agonist) and is studied for metabolic & body-weight research. Both are supplied as lyophilized powder for in-vitro laboratory research only — this page compares mechanism and research status, not dosing or human use.

Retatrutide (GLP-3)

Metabolic

Tirzepatide

Metabolic

Frequently asked

What is the difference between Retatrutide (GLP-3) and Tirzepatide?: The main difference is mechanism and research stage. Retatrutide (GLP-3) targets GLP-1 + GIP + glucagon (triple agonist) (phase 3 (investigational)) and is studied for metabolic & body-weight research; Tirzepatide targets GLP-1 + GIP (dual agonist) (approved formulations exist) and is studied for metabolic & body-weight research. Both are research-use-only compounds, not for human or animal use.
Are Retatrutide (GLP-3) and Tirzepatide approved for human use?: No. Renova Wellness supplies both strictly for in-vitro laboratory and scientific research use only. Research status differs — Retatrutide (GLP-3): phase 3 (investigational); Tirzepatide: approved formulations exist — but neither is sold for human or animal consumption, and no medical, therapeutic, or dosing claims are made.
How is purity verified for Retatrutide (GLP-3) and Tirzepatide?: Every lot of both compounds ships with its own per-batch Certificate of Analysis — identity by mass spectrometry, ≥98% purity by HPLC, and a unique lot number you can verify against the vial in your hand.

Related comparisons

Retatrutide (GLP-3) vs Semaglutide Semaglutide vs Tirzepatide

Build a multi-compound set in the Stack Builder or run the reconstitution calculator.

Research references

Primary literature for Retatrutide (GLP-3) and Tirzepatide. Provided for scientific context only — not medical or dosing guidance.

Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315 →
Rosenstock J, et al. Retatrutide for people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. PMID 37385280 →
Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials. Diabetes Ther. 2021. PMID 33325008 →
Karagiannis T, et al. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022. PMID 35579691 →

Research use only. This comparison covers mechanism, target, and research status. It is not medical, therapeutic, or dosing advice. Compounds sold by Renova Wellness™ are for in-vitro laboratory research and are not for human or animal consumption.